News

HitGen Inc. announced that the company has achieved a milestone in their strategic collaboration with Almirall to develop a novel class of drugs. The licensed compounds were identified…
Read More...

AbbVie and Harvard University announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel…
Read More...

Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company announced that it has entered into a strategic collaboration with Vir Biotechnology, a clinical-stage immunology…
Read More...

Catalent, Inc. announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19…
Read More...

PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, and portfolio company of Partners Group, announced today the signing of a…
Read More...

Bristol Myers Squibb and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic…
Read More...

Bio-Thera Solutions, Ltd. and BeiGene, Ltd. announced that the companies have executed a license, distribution, and supply agreement for China for Bio-Thera’s BAT1706, an…
Read More...

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce targeted polyclonal antibodies, announced the dosing of the…
Read More...

 Renalytix AI plc announced a collaboration with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the…
Read More...

Sanofi and Principia Biopharma Inc. entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100  per share in cash, which…
Read More...

Boehringer Ingelheim announced that the first patient has enrolled in InPedILD, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and…
Read More...

QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce that it has entered into an agreement with…
Read More...

Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, announced the signing of a licensing agreement with Roche providing Celleron exclusive…
Read More...

GeneCentric Therapeutics announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for…
Read More...

Blade Therapeutics announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19…
Read More...

Gilead Sciences, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury (remdesivir), an investigational antiviral…
Read More...

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal…
Read More...

Bristol Myers Squibb announced that CheckMate -649, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as a first-line treatment for…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the…
Read More...

Bayer and KaNDy Therapeutics Ltd announced that Bayer will acquire KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare. KaNDy Therapeutics Ltd.…
Read More...